Your Patient’s DNA Holds
the Prescription Clues

Acutis Pharmacogenetics testing helps clinicians choose medications with greater precision, reducing adverse drug reactions and minimizing trial-and-error prescribing.

Benefits of Acutis Pharmacogenetics Test

The increase in the number of medications added to the complexity of interactions requires physicians to have more actionable information, presented with greater clarity.

Acutis pharmacogenetics test expedites the process while providing the critical data to help you:
Select the medications most beneficial for your patient
Lower the risk of harmful effects caused by drug interactions
Determine what medications to avoid
Make dosage adjustments to medications patients may currently be taking
Lower the trial and error involved in prescribing effective dosages

Best candidates for Acutis pharmacogenetics test are patients who:

Use more than one medication to treat an ailment or condition (polypharmacy)
Take medications for chronic pain
Are depressed or are experiencing treatment-resistant depression
Have a history of heart attack or stent replacement
Have been diagnosed with mood disorders such as bipolar disorder
Have experienced or are afraid of experiencing another adverse drug reaction or event

Test Consists of 3 Advanced Steps

1
Drug metabolism geno-typing,
which analyzes patient-specific genetic variants that influence the function of drug-metabolizing enzymes.

2
Drug response geno-typing,
which evaluates patient-specific genetic variants involved in the way medications work at the biological site of action. (transporter genes)

3
Algorithmic results,
which screens for potential metabolic interactions caused by multiple prescriptions, which may alter the metabolism of one or more medications.

Summary of Key Pharmacogenomic Studies

Setting

Study design

Outcomes associated with PGx testing

Home health & long-term care ^2,3

Randomized controlled trial

Reduced rehospitalizations and emergency-department visits at 60 days following enrollment Elimination or replacement of 1-3 drugs per patient for a population with high polypharmacy burden: up to 91% take ≥5 medications; 65% take ≥10 medications

Elderly *

Observational study

39% lower hospitalizations amongst the population tested for PGX

Psychiatric patients ^1,5,6

Observational study
Randomized controlled trial

Cost savings of $3,988 per member per year
Improved medication adherence and drug discontinuation
Higher clinical response and remission rates at 8 weeks with PGx-guided care vs usual care

Drug treatment patients (methadone & buprenorphine)

Observational and pharmacokinetic association studies

Genetic variation associated with methadone and buprenorphine metabolism and dose requirements, supporting individualized dosing to reduce toxicity or under-dosing risk

Pharmacogenomic Conditions and Clinical Relevance

Priority Condition Area

Drug Class

Common Drugs

Key Genes Tested

Clinical Relevance

Psychiatric

Antidepressants
antipsychotics
ADHD meds

SSRIs (citalopram, escitalopram, sertraline, fluoxetine, paroxetine)
SNRIs (venlafaxine, duloxetine), TCAs (amitriptyline, nortriptyline)
Antipsychotics (risperidone, aripiprazole, quetiapine, olanzapine, clozapine) , Atomoxetine, L-methylfolate (adjunct)

CYP2D6
CYP2C19
CYP3A4
CYP1А2
MTHFR

Drives medication response and side effects

Internal medicine

Proton pump inhibitors

Omeprazole, Pantoprazole, Esomeprazole

CYP2C19

Treatment faiture or excessive exposure

Internal medicine

Statins

Simvastatin, Atorvastatin, Rosuvastatin

SLCO1B1
CYP3А4/3A5

Myopathy risk dose selection

Medication-Assisted Treatment (MAT)

Opioid agonist & partial agonist

Methadone, Buprenorphine

CYP2B6
СУРЗА5
CYP2D6

Dose optimization

Cardiology

Antiplatelet & anticoagulation therapy

Clopidogrel (antiplatelet)
Warfarin (anticoagulant)

CYP2C19
VKORC1
CYP2C9

Reduced activation or altered dose sensitivity may increase

Pain Management

Opioid analgesics

Codeine, Tramadol, Hydrocodone, Oxycodone

CYP2D6
CYPЗА4
СYРЗА5
COMT

Activation vs non-response toxicity risk dose variability

Additional notes: APOE for neuro risk and Factor II (F2), Factor V Leiden (F5) for Thrombophilia risk are also tested

Reference Footnotes
1 Winner JG, Carhart JM, Altar CA, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1-year prospective evaluation. Curr Med Res Opin. 2015;31:1633–1643.
2 Elliott LS, Henderson JC, Neradilek MB, et al. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One. 2017;12:e0170905.
3 Saldivar JS, Taylor D, Sugarman EA, et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. Pharmgenomics Pers Med. 2016;9:1–6.
4 Brixner D, Biltaji E, Bress A, et al. Effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19:213–228.
5 Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 2017;39:592–602.e1.
6 Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder: the GUIDED trial. J Psychiatr Res. 2019;111:59–67.

Your Patient’s DNA Holds the Prescription Clues